by Lupus Foundation, Ohio | Feb 24, 2026 | Lupus Foundation of America, News & Events
A new study found that people with cytomegalovirus (CMV) infection may be more likely to develop systemic lupus erythematosus (SLE), and CMV could influence how the disease starts. This post was originally published on this...
by Lupus Foundation, Ohio | Feb 19, 2026 | Lupus Foundation of America, News & Events
A new study found statin use is associated with reduced disease activity and inflammation in people with systemic lupus erythematosus (SLE), particularly in patients younger than 40 years. This post was originally published on this...
by Alex Acevedo | Feb 3, 2026 | Lupus Foundation of America, News & Events, Research News
This afternoon, Congress took the final steps in the FY 2026 budget process, passing legislation that increases funding for lupus programs, including $27 million – the most in history – for lupus programs at the Centers for Disease Control and Prevention (CDC),...
by Lupus Foundation, Ohio | Feb 3, 2026 | Lupus Foundation of America, News & Events
A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM) and systemic lupus erythematosus...
by Lupus Foundation, Ohio | Feb 3, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC), self-administration of Saphnelo (anifrolumab). AstraZeneca has...
